TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+20.64%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.64B
AUM Growth
+$2.64B
(+15%)
Cap. Flow
-$3.06M
Cap. Flow
% of AUM
-0.12%
Top 10 Holdings %
Top 10 Hldgs %
38.92%
Holding
218
New
26
Increased
62
Reduced
55
Closed
4
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$15.6M |
| 2 |
Johnson & Johnson
JNJ
|
$14.4M |
| 3 |
Cigna
CI
|
$13.4M |
| 4 |
Abbott
ABT
|
$13M |
| 5 |
Milestone Pharmaceuticals
MIST
|
$11.2M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$146M |
| 2 |
UnitedHealth
UNH
|
$26M |
| 3 |
Humana
HUM
|
$10.7M |
| 4 |
Intuitive Surgical
ISRG
|
$9.93M |
| 5 |
Zoetis
ZTS
|
$7.76M |
Sector Composition
| 1 | Healthcare | 94.16% |
| 2 | Real Estate | 3.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Zoetis
ZTS
$69.3B
| $25.2M | 0.95% | 190,384 -58,640 | -24% | -$7.76M |
|
27
Stryker
SYK
$150B
| $23.9M | 0.9% | 113,667 -4,853 | -4% | -$1.02M |
|
28
Sarepta Therapeutics
SRPT
$1.78B
| $23.4M | 0.89% | 181,623 +41,344 | +29% | +$5.34M |
|
29
BioMarin Pharmaceuticals
BMRN
$11.2B
| $23.4M | 0.88% | 276,560 +30,797 | +13% | +$2.6M |
|
|
30
Intuitive Surgical
ISRG
$170B
| $22.9M | 0.86% | 38,683 -16,792 | -30% | -$9.93M |
|
31
Viatris
VTRS
$12.3B
| $20.9M | 0.79% | 1,038,554 | – | – |
|
32
Neurocrine Biosciences
NBIX
$13.8B
| $20.8M | 0.78% | 193,042 -13,780 | -7% | -$1.48M |
|
|
33
Humana
HUM
$36.5B
| $20.2M | 0.76% | 55,013 -29,221 | -35% | -$10.7M |
|
34
Novartis
NVS
$245B
| $20M | 0.76% | 211,047 -38,400 | -15% | -$3.64M |
|
35
Becton Dickinson
BDX
$55.3B
| $18M | 0.68% | 66,257 +7,819 | +13% | +$2.13M |
|
|
PRAH
36
DELISTED
PRA Health Sciences, Inc.
PRAH
| $17M | 0.64% | 153,003 | – | – |
|
37
Alnylam Pharmaceuticals
ALNY
$58.5B
| $16.6M | 0.63% | 143,795 -22,480 | -14% | -$2.59M |
|
38
Edwards Lifesciences
EW
$47.8B
| $16.2M | 0.61% | 69,557 +4,317 | +7% | +$1.01M |
|
39
Welltower
WELL
$113B
| $15.7M | 0.59% | 191,646 +39,324 | +26% | +$3.22M |
|
40
HCA Healthcare
HCA
$94.5B
| $14.2M | 0.54% | 95,833 -2,560 | -3% | -$378K |
|
41
AstraZeneca
AZN
$248B
| $13.8M | 0.52% | 276,098 | – | – |
|
|
ONC
42
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $13.4M | 0.51% | 81,089 -13,200 | -14% | -$2.19M |
|
43
Novo Nordisk
NVO
$251B
| $12.8M | 0.48% | 221,364 -19,636 | -8% | -$1.14M |
|
44
Jazz Pharmaceuticals
JAZZ
$7.75B
| $12.8M | 0.48% | 85,673 +10,737 | +14% | +$1.6M |
|
45
Esperion Therapeutics
ESPR
$448M
| $12.7M | 0.48% | 213,562 | – | – |
|
46
Ionis Pharmaceuticals
IONS
$6.79B
| $12.7M | 0.48% | 209,924 +23,680 | +13% | +$1.43M |
|
47
GSK
GSK
$79.9B
| $12.1M | 0.46% | 257,048 +25,290 | +11% | +$1.19M |
|
48
Omega Healthcare
OHI
$12.6B
| $12.1M | 0.46% | 284,795 +12,029 | +4% | +$509K |
|
|
49
Milestone Pharmaceuticals
MIST
$156M
| $12M | 0.45% | 746,653 +699,713 | +1,491% | +$11.2M |
|
|
GBT
50
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $11.7M | 0.44% | 147,168 +54,211 | +58% | +$4.31M |
|